drugset / Trial / NCT00767325

A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonography

NCT00767325

Phase 3 Completed 104 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of the study is to assess early signs of response to abatacept+methotrexate in metacarpophalangeal joints in both hands using power Doppler ultrasonography in patients with active rheumatoid arthritis.

Timeline

Start
2008-12
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Abatacept Other / unclassified 10 mg/kg Intravenous
Background Methotrexate Small molecule 15 mg

Indications